This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Pacific Edge Limited. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: The Innovative Contributions of James Miller Suttie
Introduction
James Miller Suttie is a notable inventor based in Dunedin, New Zealand. He has made significant contributions to the field of medical diagnostics, particularly in the detection and treatment of urothelial carcinoma. His innovative approach combines genetic and phenotypic biomarkers to improve patient outcomes.
Latest Patents
Suttie's most recent patent is titled "Methods for detecting genetic and phenotypic biomarkers of urothelial carcinoma and treatment thereof." This patent introduces new methods for identifying patients with hematuria who are at low risk of having urothelial cancer (UC). The invention features the G+P INDEX, which integrates selected phenotypic variables with levels of genotypic expression. This new metric assesses factors such as age, sex, smoking history, and frequency of hematuria alongside genetic markers like MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb. The G+P INDEX categorizes patients into three risk groups: High Risk, Risk, and Low Risk of UC. This innovative approach can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients identified as Low Risk.
Career Highlights
James Miller Suttie is associated with Pacific Edge Limited, a company focused on advancing cancer diagnostics. His work has been instrumental in developing methods that enhance the accuracy of cancer detection and treatment strategies. Suttie's dedication to improving patient care through innovative solutions is evident in his research and patent contributions.
Collaborations
Suttie has collaborated with notable colleagues, including David Darling and Mark Dalphin. Their combined expertise has contributed to the advancement of medical technologies and the development of effective diagnostic tools.
Conclusion
James Miller Suttie's innovative work in the field of urothelial carcinoma detection exemplifies the impact of combining genetic and phenotypic data for improved patient outcomes. His contributions continue to shape the future of medical diagnostics and patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile